FIGURE

Fig. 7

ID
ZDB-FIG-190723-1889
Publication
Felker et al., 2018 - Continuous addition of progenitors forms the cardiac ventricle in zebrafish
Other Figures
All Figure Page
Back to All Figure Page
Fig. 7

FGF signaling differentially affects tbx1+ ventricular and BA precursors. af Maximum intensity projections of representative tbx1:EGFP;drl:mCherry DMSO-treated controls or embryos treated with 5 µM SU5402 from 14 ss to 22 hpf; lateral/dorsal view, anterior to the left. FGF signaling-perturbed embryos show a defect in the tbx1:EGFP-expressing sheath (arrowhead) at the base of the forming heart tube (outline). go Maximum intensity projections of representative hearts of tbx1:EGFP;myl7:DsRed2 embryos, DMSO-treated controls (gi, n = 5), treated with 5 µM SU5402 between 14 ss and 24 hpf (jl, n = 8), or treated with 2 µM SU5402 continuously from 14 ss (mo, n = 3); ventral views, anterior to the top, outlines mark the heart. FGF-perturbed embryos retain normal contribution of tbx1:EGFP-expressing cardiomyocytes to the ventricle upon pulsed or continuous signaling inhibition; ventricle (V), atrium (A), bulbus arteriosus (BA), and asterisks mark the missing BA upon SU5402 treatments. pr Quantified ventricle, atrium, and BA area size in SU5402-treated embryos as in go. Pulsed (see jl) or continuous (see mo) FGF signaling inhibition diminishes ventricle size (p) and severely reduced to abolished addition of the tbx1 reporter-expressing BA (r). The atrium is not significantly affected (q). Means ± SEM. ns P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001, unpaired t-test with Welch correction. sy SU5402 treatments affect BA development in time- and concentration-dependent manner; n indicates the number of embryos analyzed per condition, N indicates the number of experiments performed. sxtbx1:EGFP;myl7:DsRed transgenic controls and embryos treated with DMSO or 5 µM SU5402 during (14 ss–22 hpf) or after (24 hp–28 hpf) heart tube formation; lateral views, anterior to the left. Absent BA formation can only be observed in embryos treated with SU5402 from mid-somitogenesis to heart tube stages (arrowhead in u, v, compare to s, t), but not when signaling inhibition is initiated at 24 hpf (arrowhead in w, x). y Quantification of the concentration-dependent effect on BA formation in FGF signaling-perturbed tbx1:EGFP;myl7:Red or DAR-4M-stained myl7:EGFP transgenics (see Supplementary Fig. 7). For 5 µM SU5402 from 14 ss to 22 hpf, no BA in n = 29/43 as assessed by tbx1 reporter and n = 5/15 by DAR-4M, total n = 34/58, N = 4; DMSO-treated controls: normal BA in n = 58/58 by tbx1 reporter and n = 10/10 by DAR-4M, total n = 68/68, N = 4. Scale bars 50 µm (g, o), 100 μm (af, sx)

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Nat. Commun.